Skip to content
PubMed This is a summary of 32 peer-reviewed journal articles Updated
Pediatric Neurology · Childhood-Onset Biotin-Responsive Peripheral Motor Neuropathy

Childhood-Onset Biotin-Responsive Peripheral Motor Neuropathy (COMNB): A Patient Guide

At a Glance

COMNB is a rare inherited SLC5A6-related disorder that can cause childhood motor-nerve weakness. Treatment requires specialist-guided lifelong biotin, pantothenic acid, and alpha-lipoic acid; high-dose biotin must be reported before blood tests because it can distort results.

Childhood-Onset Biotin-Responsive Peripheral Motor Neuropathy (COMNB) is an extremely rare genetic condition that affects the way your child’s cells receive essential nutrients. It is caused by changes in both copies of the SLC5A6 gene, which provides the instructions for building a transporter on the surface of cells [1][2]. This transporter is responsible for pulling three vital nutritional cofactors—biotin, pantothenic acid (Vitamin B5), and alpha-lipoic acid—into the cells to produce energy. When this transporter is impaired, the body’s cells are deprived of these nutrients, even if your child eats a healthy diet [3][4].

The most significant impact of this nutrient deficiency in the COMNB phenotype is on the motor axons, the transmission structures inside nerves that carry movement signals from the brain to the muscles [2]. Without adequate cellular energy, these nerves struggle to function, leading to motor axonal neuropathy [5]. Symptoms typically become apparent around age 10, though age of onset can vary [1]. A child might become progressively weaker, tire more easily during physical activities, or lose motor skills they once had, such as running or climbing stairs [6][2]. Because the condition is exceptionally rare, it often mimics other metabolic disorders, and many families face a long journey before advanced genetic testing confirms the diagnosis [7]. Note that in medical records, this condition may also be called “SLC5A6-related disorder” or “SMVT deficiency.”

The foundation of managing COMNB is a lifelong, specialist-directed “triple supplementation” protocol. Despite the condition’s name, treating with biotin alone is discouraged; there is evidence that high-dose biotin monotherapy can compete with the other missing nutrients at the transporter, potentially worsening the underlying biochemical imbalance [8][3]. Instead, metabolic specialists prescribe targeted doses of all three nutrients—biotin, pantothenic acid, and lipoic acid—to bypass the defective transporter and support the cells [5][1]. Based on clinical case reports, this treatment aims to stabilize the disease and can lead to meaningful improvements in strength, though established nerve damage heals slowly and may only partially reverse [2][9].

Living with COMNB requires a strong partnership with a metabolic care team, particularly regarding medical testing. The high-dose biotin therapy required for treatment disrupts specific laboratory platforms (streptavidin-biotin immunoassays), which can cause blood tests to show dangerously incorrect results—such as falsely low troponin (hiding a heart issue) or falsely altered thyroid levels [10][11][12]. Families must inform every doctor and laboratory about the high-dose biotin regimen so they can use alternative testing methods, and must never alter or pause the vitamin protocol without direct supervision from their metabolic specialist [13][14].

Common questions in this guide

What is COMNB?
COMNB is an extremely rare inherited disorder related to changes in both copies of the SLC5A6 gene. These changes impair transport of several nutrients into cells and can affect the motor nerves that control movement.
What symptoms can COMNB cause in a child?
Children may develop progressive weakness, tire easily during physical activity, or lose motor skills they previously had, such as running or climbing stairs. Symptoms often become noticeable around age 10, although the age of onset can vary.
Why does COMNB treatment use three nutrients instead of biotin alone?
The affected transporter normally brings biotin, pantothenic acid, and alpha-lipoic acid into cells. Specialist-directed treatment replaces all three nutrients because high-dose biotin alone may compete with the other nutrients and worsen the underlying imbalance.
Can high-dose biotin change my child’s blood-test results?
Yes. High-dose biotin can interfere with some laboratory tests and may produce misleading results, including falsely low troponin or altered thyroid results. Tell every doctor and laboratory about the biotin treatment before testing so alternative methods can be considered.
How is COMNB diagnosed?
Because COMNB can resemble other metabolic disorders, diagnosis may require advanced genetic testing. Testing looks for disease-causing changes in both copies of the SLC5A6 gene and should be interpreted by an experienced metabolic or genetics team.
Can treatment repair nerve damage caused by COMNB?
Triple supplementation may stabilize the condition and improve strength. Established nerve damage generally recovers slowly and may improve only partly, so treatment response should be monitored by the specialist team.

Get notified when new evidence is published on peripheral motor neuropathy, childhood-onset, biotin-responsive.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (14)
  1. 1

    Novel missense variants cause intermediate phenotypes in the phenotypic spectrum of SLC5A6-related disorders.

    Utsuno Y, Hamada K, Hamanaka K, et al.

    Journal of human genetics 2024; (69(2)):69-77 doi:10.1038/s10038-023-01206-5.

    PMID: 38012394
  2. 2

    Genome sequencing enables diagnosis and treatment of SLC5A6 neuropathy.

    Riley LG, Sabui S, Said HM, et al.

    European journal of human genetics : EJHG 2024; (32(8)):947-953 doi:10.1038/s41431-024-01641-8.

    PMID: 38816490
  3. 3

    Major involvement of Na(+) -dependent multivitamin transporter (SLC5A6/SMVT) in uptake of biotin and pantothenic acid by human brain capillary endothelial cells.

    Uchida Y, Ito K, Ohtsuki S, et al.

    Journal of neurochemistry 2015; (134(1)):97-112 doi:10.1111/jnc.13092.

    PMID: 25809983
  4. 4

    Novel biallelic variants expand the SLC5A6-related phenotypic spectrum.

    Holling T, Nampoothiri S, Tarhan B, et al.

    European journal of human genetics : EJHG 2022; (30(4)):439-449 doi:10.1038/s41431-021-01033-2.

    PMID: 35013551
  5. 5

    SLC5A6 Mutations in Axonal Sensorimotor Polyneuropathy Patients Concurrent With Sodium Dependent Multivitamin Transporter Deficiency and Improved Effects by Multivitamin Therapy.

    Pi BK, Lee AJ, Nam SH, et al.

    Journal of the peripheral nervous system : JPNS 2025; (30(2)):e70030 doi:10.1111/jns.70030.

    PMID: 40396389
  6. 6

    Genotype/phenotype correlations in AARS-related neuropathy in a cohort of patients from the United Kingdom and Ireland.

    Bansagi B, Antoniadi T, Burton-Jones S, et al.

    Journal of neurology 2015; (262(8)):1899-908 doi:10.1007/s00415-015-7778-4.

    PMID: 26032230
  7. 7

    Genetic defect of the sodium-dependent multivitamin transporter: A treatable disease, mimicking biotinidase deficiency.

    Schwantje M, de Sain-van der Velden M, Jans J, et al.

    JIMD reports 2019; (48(1)):11-14 doi:10.1002/jmd2.12040.

    PMID: 31392107
  8. 8

    Sodium-dependent multivitamin transporter deficiency caused by novel SLC5A6 mutations: a clinical case and personalized mice model study.

    Priymak AV, Averina OA, Novikova MA, et al.

    Frontiers in cell and developmental biology 2026; (14()):1925753 doi:10.3389/fcell.2026.1925753.

    PMID: 42920491
  9. 9

    A novel SLC5A6 homozygous variant in a family with multivitamin-dependent neurometabolic disorder: Phenotype expansion and long-term follow-up.

    Montomoli M, Vetro A, Tubili F, et al.

    European journal of medical genetics 2023; (66(8)):104808 doi:10.1016/j.ejmg.2023.104808.

    PMID: 37391029
  10. 10

    A survey-based study of physician practices regarding biotin supplementation.

    Waqas B, Wu A, Yim E, Lipner SR

    The Journal of dermatological treatment 2022; (33(1)):573-574 doi:10.1080/09546634.2020.1770178.

    PMID: 32419559
  11. 11

    Comprehensive assessment of biotin interference in immunoassays.

    Li J, Wagar EA, Meng QH

    Clinica chimica acta; international journal of clinical chemistry 2018; (487()):293-298 doi:10.1016/j.cca.2018.10.013.

    PMID: 30296442
  12. 12

    Susceptibility of Cardiac Troponin Assays to Biotin Interference.

    Frame IJ, Joshi PH, Mwangi C, et al.

    American journal of clinical pathology 2019; (151(5)):486-493 doi:10.1093/ajcp/aqy172.

    PMID: 30715102
  13. 13

    A new case of sodium-dependent multivitamin transporter defect occurring as a life-threatening condition responsive to early vitamin supplementation and literature review.

    Van Vyve FX, Mercier N, Papadopoulos J, et al.

    Molecular genetics & genomic medicine 2024; (12(2)):e2388 doi:10.1002/mgg3.2388.

    PMID: 38407570
  14. 14

    Best practices in mitigating the risk of biotin interference with laboratory testing.

    Bowen R, Benavides R, Colón-Franco JM, et al.

    Clinical biochemistry 2019; (74()):1-11 doi:10.1016/j.clinbiochem.2019.08.012.

    PMID: 31473202

This page is for informational purposes only and does not constitute medical advice. Your child’s metabolic specialist should guide supplementation, testing, and emergency or sick-day decisions, and every clinician should know about high-dose biotin.